Clinical Trial Update: Mechanisms of Resistance to Amivantamab in Patients With NSCLC With EGFR Exon 20 Insertion [NA]

View source ↗

Summary

An update on a clinical trial investigating how resistance to amivantamab may develop in non-small cell lung cancer patients with EGFR exon 20 insertion mutatio…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• RYBREVANT (amivantamab-vmjw)

Snippet

Sponsor: Groupe Francais De Pneumo-Cancerologie | Conditions: Non-small Cell Lung Cancer, EGFR Exon 20 Insertion Mutation | NA | Status: RECRUITING